{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:46:20Z","timestamp":1793778380772,"version":"4.6.1"},"reference-count":124,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,7,20]],"date-time":"2015-07-20T00:00:00Z","timestamp":1437350400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.antiviral.2015.06.019","type":"journal-article","created":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T13:35:04Z","timestamp":1435757704000},"page":"97-108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":122,"special_numbering":"C","title":["Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent"],"prefix":"10.1016","volume":"121","author":[{"given":"Robert G.","family":"Gish","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man-Fung","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry Lik Yuen","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce D.","family":"Given","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Lung","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Locarnini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnson Y.N.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine I.","family":"Wooddell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schluep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2015.06.019_b0005","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1172\/JCI33494","article-title":"Nonviral delivery of synthetic siRNAs in vivo","volume":"117","author":"Akhtar","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.antiviral.2015.06.019_b0010","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1021\/jm049167j","article-title":"Fully 2\u2032-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA","volume":"48","author":"Allerson","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2015.06.019_b0015","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1099\/vir.0.81920-0","article-title":"The immune response during hepatitis B virus infection","volume":"87","author":"Bertoletti","year":"2006","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2015.06.019_b0020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3390\/v1020091","article-title":"HBV-specific adaptive immunity","volume":"1","author":"Bertoletti","year":"2009","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2015.06.019_b0025","doi-asserted-by":"crossref","unstructured":"Block, T.M., Rawat, S., Brosgart, C., 2015. Chronic hepatitis B: a wave of new therapies on the horizon. Antiviral Res. 121, 69\u201381.","DOI":"10.1016\/j.antiviral.2015.06.014"},{"key":"10.1016\/j.antiviral.2015.06.019_b0030","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1128\/JVI.02844-06","article-title":"Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection","volume":"81","author":"Boni","year":"2007","journal-title":"J. Virol."},{"issue":"963\u2013973","key":"10.1016\/j.antiviral.2015.06.019_b0035","first-page":"e969","article-title":"Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues","volume":"143","author":"Boni","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.06.019_b0040","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.cell.2009.01.035","article-title":"Origins and mechanisms of miRNAs and siRNAs","volume":"136","author":"Carthew","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2015.06.019_b0045","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/mt.2008.298","article-title":"Asymmetric shorter-duplex siRNA structures trigger efficient gene silencing with reduced nonspecific effects","volume":"17","author":"Chang","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.antiviral.2015.06.019_b0050","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.23327","article-title":"Entecavir treatment for up to 5years in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"51","author":"Chang","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.06.019_b0055","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1053\/gast.2002.36026","article-title":"Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection","volume":"123","author":"Chen","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.06.019_b0060","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.iy.13.040195.000333","article-title":"Hepatitis B virus immunopathogenesis","volume":"13","author":"Chisari","year":"1995","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.antiviral.2015.06.019_b0065","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.bbrc.2006.02.049","article-title":"Chemical modification of siRNAs to improve serum stability without loss of efficacy","volume":"342","author":"Choung","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.antiviral.2015.06.019_b0070","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1261\/rna.1161908","article-title":"Potent RNAi by short RNA triggers","volume":"14","author":"Chu","year":"2008","journal-title":"RNA"},{"key":"10.1016\/j.antiviral.2015.06.019_b0075","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis","volume":"369","author":"Coelho","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2015.06.019_b0080","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1093\/nar\/gkg393","article-title":"Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells","volume":"31","author":"Czauderna","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2015.06.019_b0085","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1242\/jcs.066399","article-title":"Breaking down the barriers: siRNA delivery and endosome escape","volume":"123","author":"Dominska","year":"2010","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.antiviral.2015.06.019_b0090","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/35078107","article-title":"Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells","volume":"411","author":"Elbashir","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2015.06.019_b0095","doi-asserted-by":"crossref","first-page":"6877","DOI":"10.1093\/emboj\/20.23.6877","article-title":"Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate","volume":"20","author":"Elbashir","year":"2001","journal-title":"EMBO J."},{"key":"10.1016\/j.antiviral.2015.06.019_b0100","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.coviro.2012.05.008","article-title":"Diverse roles of hepatitis B virus in liver cancer","volume":"2","author":"Fallot","year":"2012","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.antiviral.2015.06.019_b0105","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","article-title":"Hepatocellular carcinoma in cirrhosis: incidence and risk factors","volume":"127","author":"Fattovich","year":"2004","journal-title":"Gastroenterology"},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2015.06.019_b0110","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/liv.12749","article-title":"HBV and the immune response","volume":"35","author":"Ferrari","year":"2015","journal-title":"Liver Int."},{"key":"10.1016\/j.antiviral.2015.06.019_b0115","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.4049\/jimmunol.145.10.3442","article-title":"Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection","volume":"145","author":"Ferrari","year":"1990","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2015.06.019_b0120","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(13)61914-5","article-title":"Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial","volume":"383","author":"Fitzgerald","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2015.06.019_b0125","doi-asserted-by":"crossref","first-page":"5742","DOI":"10.1128\/JVI.00430-14","article-title":"Envelope proteins derived from naturally integrated hepatitis B virus DNA support assembly and release of infectious hepatitis delta virus particles","volume":"88","author":"Freitas","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.06.019_b0130","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1038\/ajg.2009.204","article-title":"To \u201cbe\u201d or not to \u201cbe\u201d: that is the question","volume":"104","author":"Frenette","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2015.06.019_b0135","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1038\/ajg.2009.200","article-title":"The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion","volume":"104","author":"Fung","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2015.06.019_b0140","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra031087","article-title":"Hepatitis B virus infection \u2013 natural history and clinical consequences","volume":"350","author":"Ganem","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2015.06.019_b0145","doi-asserted-by":"crossref","unstructured":"Gish, R.G., Given, B.D., Lai, C.L., Locarnini, S.A., Lau, J.Y., Lewis, D.L., Schluep, T., 2015. Chronic hepatitis B: virology, natural history, current management and a glimpse at future opportunities. Antiviral Res. 121, 47\u201358.","DOI":"10.1016\/j.antiviral.2015.06.008"},{"key":"10.1016\/j.antiviral.2015.06.019_b0150","doi-asserted-by":"crossref","first-page":"6233","DOI":"10.1038\/sj.onc.1204835","article-title":"Identification of human cancer-related genes by naturally occurring hepatitis B virus DNA tagging","volume":"20","author":"Gozuacik","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.antiviral.2015.06.019_b0155","doi-asserted-by":"crossref","first-page":"6158","DOI":"10.1128\/JVI.69.10.6158-6169.1995","article-title":"High-level hepatitis B virus replication in transgenic mice","volume":"69","author":"Guidotti","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.06.019_b0160","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1053\/j.gastro.2006.09.020","article-title":"Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5years","volume":"131","author":"Hadziyannis","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.06.019_b0165","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/sj.gt.3301506","article-title":"On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids","volume":"8","author":"Hafez","year":"2001","journal-title":"Gene Ther."},{"key":"10.1016\/j.antiviral.2015.06.019_b0170","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nsmb780","article-title":"Kinetic analysis of the RNAi enzyme complex","volume":"11","author":"Haley","year":"2004","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.antiviral.2015.06.019_b0175","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1126\/science.1252967","article-title":"RNA interference. Drugging RNAi","volume":"347","author":"Haussecker","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2015.06.019_b0180","first-page":"105","article-title":"The role of HBsAg levels in the current management of chronic HBV infection","volume":"27","author":"Honer Zu Siederdissen","year":"2014","journal-title":"Ann. Gastroenterol."},{"key":"10.1016\/j.antiviral.2015.06.019_b0185","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nm1191","article-title":"Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7","volume":"11","author":"Hornung","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2015.06.019_b0190","doi-asserted-by":"crossref","first-page":"7560","DOI":"10.1093\/nar\/gkp835","article-title":"Profiling of mismatch discrimination in RNAi enabled rational design of allele-specific siRNAs","volume":"37","author":"Huang","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2015.06.019_b0195","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1261\/rna.30706","article-title":"Position-specific chemical modification of siRNAs reduces \u201coff-target\u201d transcript silencing","volume":"12","author":"Jackson","year":"2006","journal-title":"RNA"},{"key":"10.1016\/j.antiviral.2015.06.019_b0200","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.cld.2010.05.005","article-title":"Antiviral therapy for chronic hepatitis B","volume":"14","author":"Jafri","year":"2010","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.antiviral.2015.06.019_b0205","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/hum.2007.179","article-title":"Overcoming the innate immune response to small interfering RNA","volume":"19","author":"Judge","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.antiviral.2015.06.019_b0210","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ymthe.2005.11.002","article-title":"Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo","volume":"13","author":"Judge","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.antiviral.2015.06.019_b0215","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nbt1081","article-title":"Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA","volume":"23","author":"Judge","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.antiviral.2015.06.019_b0220","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/0168-8278(91)90074-L","article-title":"Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B","volume":"13","author":"Jung","year":"1991","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.06.019_b0225","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2217\/fvl.14.36","article-title":"Strategies to eliminate HBV infection","volume":"9","author":"Kapoor","year":"2014","journal-title":"Future Virol."},{"key":"10.1016\/j.antiviral.2015.06.019_b0230","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nbt1051","article-title":"Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy","volume":"23","author":"Kim","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.antiviral.2015.06.019_b0235","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jcv.2012.01.024","article-title":"Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B","volume":"54","author":"Kittner","year":"2012","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.antiviral.2015.06.019_b0240","doi-asserted-by":"crossref","first-page":"935295","DOI":"10.1155\/2013\/935295","article-title":"Hepatitis B surface antigen could contribute to the immunopathogenesis of hepatitis B virus infection","volume":"2013","author":"Kondo","year":"2013","journal-title":"ISRN Gastroenterol."},{"key":"10.1016\/j.antiviral.2015.06.019_b0245","series-title":"Hepatitis B Virus: Molecular Mechanisms in Disease and Novel Strategies for Therapy","author":"Koshy","year":"1998"},{"key":"10.1016\/j.antiviral.2015.06.019_b0250","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000360947","article-title":"Genotypes and genetic variability of hepatitis B virus","volume":"57","author":"Kramvis","year":"2014","journal-title":"Intervirology"},{"key":"10.1016\/j.antiviral.2015.06.019_b0255","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s11095-006-9180-5","article-title":"Lipid-based nanoparticles for nucleic acid delivery","volume":"24","author":"Li","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.antiviral.2015.06.019_b0260","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/hep.1840080310","article-title":"The development of cirrhosis in patients with chronic type B hepatitis: a prospective study","volume":"8","author":"Liaw","year":"1988","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.06.019_b0265","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1126\/science.1102513","article-title":"Argonaute2 is the catalytic engine of mammalian RNAi","volume":"305","author":"Liu","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2015.06.019_b0270","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1136\/gutjnl-2013-305785","article-title":"Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma","volume":"63","author":"Liu","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.antiviral.2015.06.019_b0275","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.molcel.2011.09.011","article-title":"Autoantigen La promotes efficient RNAi, antiviral response, and transposon silencing by facilitating multiple-turnover RISC catalysis","volume":"44","author":"Liu","year":"2011","journal-title":"Mol. Cell"},{"key":"10.1016\/j.antiviral.2015.06.019_b0280","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.06.019_b0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2015.02.003","article-title":"Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics","volume":"203","author":"Lorenzer","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.antiviral.2015.06.019_b0290","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2015.06.019_b0295","first-page":"63","article-title":"Natural history of hepatitis B","volume":"51","author":"Marcellin","year":"2005","journal-title":"Minerva Gastroenterol. Dietol."},{"key":"10.1016\/j.antiviral.2015.06.019_b0300","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2015.06.019_b0305","doi-asserted-by":"crossref","first-page":"8308","DOI":"10.1128\/JVI.00833-10","article-title":"Clonal expansion of normal-appearing human hepatocytes during chronic hepatitis B virus infection","volume":"84","author":"Mason","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.06.019_b0310","doi-asserted-by":"crossref","first-page":"8396","DOI":"10.1128\/JVI.00700-09","article-title":"Detection of clonally expanded hepatocytes in chimpanzees with chronic hepatitis B virus infection","volume":"83","author":"Mason","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.06.019_b0315","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.cell.2005.08.044","article-title":"Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes","volume":"123","author":"Matranga","year":"2005","journal-title":"Cell"},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2015.06.019_b0320","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-2005-915644","article-title":"Epidemiology and natural history of hepatitis B","volume":"25","author":"McMahon","year":"2005","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.antiviral.2015.06.019_b0325","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/infdis\/151.4.599","article-title":"Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state","volume":"151","author":"McMahon","year":"1985","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2015.06.019_b0330","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.molcel.2004.07.007","article-title":"Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs","volume":"15","author":"Meister","year":"2004","journal-title":"Mol. Cell"},{"key":"10.1016\/j.antiviral.2015.06.019_b0335","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature02873","article-title":"Mechanisms of gene silencing by double-stranded RNA","volume":"431","author":"Meister","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2015.06.019_b0340","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.4049\/jimmunol.160.4.2013","article-title":"The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence","volume":"160","author":"Milich","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2015.06.019_b0345","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1101\/gad.1370605","article-title":"Slicer function of Drosophila Argonautes and its involvement in RISC formation","volume":"19","author":"Miyoshi","year":"2005","journal-title":"Genes Dev."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2015.06.019_b0350","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1007\/PL00000061","article-title":"Constrained evolution with respect to gene overlap of hepatitis B virus","volume":"44","author":"Mizokami","year":"1997","journal-title":"J. Mol. Evol."},{"key":"10.1016\/j.antiviral.2015.06.019_b0355","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.22744","article-title":"Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients","volume":"49","author":"Moucari","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.06.019_b0360","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/gut.2004.054452","article-title":"Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas","volume":"54","author":"Murakami","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.antiviral.2015.06.019_b0365","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.antiviral.2015.06.019_b0370","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jhep.2014.05.044","article-title":"Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial)","volume":"61","author":"Ning","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.06.019_b0375","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/nature08107","article-title":"Reconstitution of Rab- and SNARE-dependent membrane fusion by synthetic endosomes","volume":"459","author":"Ohya","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2015.06.019_b0380","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1365-2567.2008.02896.x","article-title":"Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus","volume":"126","author":"Op den Brouw","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.antiviral.2015.06.019_b0385","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","article-title":"Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity","volume":"30","author":"Ott","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2015.06.019_b0390","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jcv.2013.09.020","article-title":"Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs","volume":"58","author":"Ouzan","year":"2013","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.antiviral.2015.06.019_b0395","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1128\/JVI.42.1.100-105.1982","article-title":"Transcription of the hepatitis B surface antigen gene in mouse cells transformed with cloned viral DNA","volume":"42","author":"Pourcel","year":"1982","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.06.019_b0400","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cell.2005.10.020","article-title":"Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation","volume":"123","author":"Rand","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2015.06.019_b0405","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jhep.2010.07.046","article-title":"Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir","volume":"54","author":"Reijnders","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.06.019_b0410","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1038\/ajg.2010.186","article-title":"A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B","volume":"105","author":"Rijckborst","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2015.06.019_b0415","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1128\/CVI.00396-05","article-title":"Reduced expression of toll-like receptor 2 on peripheral monocytes in patients with chronic hepatitis B","volume":"13","author":"Riordan","year":"2006","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.antiviral.2015.06.019_b0420","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/978-3-642-38965-8_4","article-title":"The oncogenic role of hepatitis B virus","volume":"193","author":"Riviere","year":"2014","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.antiviral.2015.06.019_b0425","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1021\/bc0255945","article-title":"Endosomolysis by masking of a membrane-active agent (EMMA) for cytoplasmic release of macromolecules","volume":"14","author":"Rozema","year":"2003","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.antiviral.2015.06.019_b0430","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/humu.20701","article-title":"Integration of hepatitis B virus DNA into the myeloid\/lymphoid or mixed-lineage leukemia (MLL4) gene and rearrangements of MLL4 in human hepatocellular carcinoma","volume":"29","author":"Saigo","year":"2008","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.antiviral.2015.06.019_b0435","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1093\/nar\/gkq055","article-title":"Modified dsRNAs that are not processed by Dicer maintain potency and are incorporated into the RISC","volume":"38","author":"Salomon","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2015.06.019_b0440","first-page":"57","article-title":"A phase I, first in human clinical trial of ARC-520, an siRNA-based therapeutic for the treatment of chronic hepatitis B virus infection, in normal healthy volunteers","volume":"9","author":"Schluep","year":"2013","journal-title":"Global Antiviral J."},{"key":"10.1016\/j.antiviral.2015.06.019_b0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.virol.2015.02.031","article-title":"Molecular biology of hepatitis B virus infection","author":"Seeger","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2015.06.019_b0450","series-title":"Fields Virology","first-page":"2977","article-title":"Hepadnaviruses, 76","author":"Seeger","year":"2007"},{"key":"10.1016\/j.antiviral.2015.06.019_b0455","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11901-014-0238-2","article-title":"Immunosuppression in patients with chronic hepatitis B","volume":"13","author":"Seetharam","year":"2014","journal-title":"Curr. Hepatol. Rep."},{"key":"10.1016\/j.antiviral.2015.06.019_b0460","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nbt.1602","article-title":"Rational design of cationic lipids for siRNA delivery","volume":"28","author":"Semple","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.antiviral.2015.06.019_b0465","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/gutjnl-2014-307237","article-title":"Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study","volume":"64","author":"Seto","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.antiviral.2015.06.019_b0470","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/hep.26376","article-title":"Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10years of nucleoside analogue therapy","volume":"58","author":"Seto","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.06.019_b0475","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.3748\/wjg.v18.i20.2443","article-title":"T cell immunopathogenesis and immunotherapeutic strategies for chronic hepatitis B virus infection","volume":"18","author":"Shimizu","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2015.06.019_b0480","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/hep.26436","article-title":"Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels","volume":"58","author":"Sonneveld","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.06.019_b0485","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nature03121","article-title":"Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs","volume":"432","author":"Soutschek","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2015.06.019_b0490","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1128\/JVI.65.3.1255-1262.1991","article-title":"Mutations affecting hepadnavirus plus-strand DNA synthesis dissociate primer cleavage from translocation and reveal the origin of linear viral DNA","volume":"65","author":"Staprans","year":"1991","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.06.019_b0495","doi-asserted-by":"crossref","first-page":"13551","DOI":"10.1073\/pnas.0704741104","article-title":"Excess vacuolar SNAREs drive lysis and Rab bypass fusion","volume":"104","author":"Starai","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2015.06.019_b0500","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/nbt.1512","article-title":"Asymmetric RNA duplexes mediate RNA interference in mammalian cells","volume":"26","author":"Sun","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.antiviral.2015.06.019_b0505","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/j.1365-2036.2008.03816.x","article-title":"Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma","volume":"28","author":"Sung","year":"2008","journal-title":"Aliment Pharmacol. Ther."},{"key":"10.1016\/j.antiviral.2015.06.019_b0510","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1111\/j.1440-1746.2011.06766.x","article-title":"Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir","volume":"26","author":"Takkenberg","year":"2011","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2015.06.019_b0515","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1146\/annurev.bioeng.8.061505.095735","article-title":"Recent approaches to intracellular delivery of drugs and DNA and organelle targeting","volume":"8","author":"Torchilin","year":"2006","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"10.1016\/j.antiviral.2015.06.019_b0520","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.virol.2013.02.027","article-title":"Influence of overlapping genes on the evolution of human hepatitis B virus","volume":"441","author":"Torres","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2015.06.019_b0525","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.12380","article-title":"Clonal expansion of hepatocytes with a selective advantage occurs during all stages of chronic hepatitis B virus infection","author":"Tu","year":"2015","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2015.06.019_b0530","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/hep.20128","article-title":"Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B","volume":"39","author":"van Zonneveld","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.06.019_b0535","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1089\/oli.2008.0162","article-title":"Selective protection of nuclease-sensitive sites in siRNA prolongs silencing effect","volume":"19","author":"Volkov","year":"2009","journal-title":"Oligonucleotides"},{"key":"10.1016\/j.antiviral.2015.06.019_b0540","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1208\/s12248-010-9210-4","article-title":"Delivery of siRNA therapeutics: barriers and carriers","volume":"12","author":"Wang","year":"2010","journal-title":"AAPS J."},{"key":"10.1016\/j.antiviral.2015.06.019_b0545","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/nature08434","article-title":"Nucleation, propagation and cleavage of target RNAs in Ago silencing complexes","volume":"461","author":"Wang","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2015.06.019_b0550","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","article-title":"Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy","volume":"126","author":"Werle-Lapostolle","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.06.019_b0555","doi-asserted-by":"crossref","first-page":"5535","DOI":"10.1128\/JVI.78.11.5535-5545.2004","article-title":"Memory CD8 T-cell differentiation during viral infection","volume":"78","author":"Wherry","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.06.019_b0560","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1146\/annurev-biophys-083012-130404","article-title":"Molecular mechanisms of RNA interference","volume":"42","author":"Wilson","year":"2013","journal-title":"Annu. Rev. Biophys."},{"key":"10.1016\/j.antiviral.2015.06.019_b0565","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1089\/nat.2012.0389","article-title":"Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo","volume":"22","author":"Wong","year":"2012","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.antiviral.2015.06.019_b0570","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1055\/s-0033-1345715","article-title":"Chronic hepatitis B: a treatment update","volume":"33","author":"Wong","year":"2013","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.antiviral.2015.06.019_b0575","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/mt.2013.31","article-title":"Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection","volume":"21","author":"Wooddell","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.antiviral.2015.06.019_b0580","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1053\/j.gastro.2004.12.007","article-title":"RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant","volume":"128","author":"Wu","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.06.019_b0585","doi-asserted-by":"crossref","first-page":"13825","DOI":"10.1073\/pnas.202398599","article-title":"Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection","volume":"99","author":"Yang","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2015.06.019_b0590","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1128\/JVI.69.7.4029-4036.1995","article-title":"Illegitimate replication of linear hepadnavirus DNA through nonhomologous recombination","volume":"69","author":"Yang","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.06.019_b0595","doi-asserted-by":"crossref","first-page":"e1694","DOI":"10.1038\/cddis.2015.42","article-title":"T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance","volume":"6","author":"Ye","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.antiviral.2015.06.019_b0600","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nsmb.2032","article-title":"Structure of C3PO and mechanism of human RISC activation","volume":"18","author":"Ye","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.antiviral.2015.06.019_b0605","article-title":"Phase II, dose ranging study of ARC-520, a siRNA-based therapeutic, in patients with chronic hepatitis B virus infection","volume":"60","author":"Yuen","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.06.019_b0610","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1053\/j.gastro.2008.07.008","article-title":"HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma","volume":"135","author":"Yuen","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.06.019_b0615","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1002\/hep.20240","article-title":"HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects","volume":"39","author":"Yuen","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.06.019_b0620","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1089\/10430349950017734","article-title":"High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA","volume":"10","author":"Zhang","year":"1999","journal-title":"Hum. Gene Ther."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215001503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215001503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T22:45:49Z","timestamp":1691793949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354215001503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":124,"alternative-id":["S0166354215001503"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.06.019","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}